Osteoporosis
Osteoporosis is a condition characterized by weak and brittle bones, increasing the risk of fractures. It often develops silently over many years, making bones more susceptible to breaks.
We are investigating whether a combination of dasatinib and quercetin can help improve bone health in patients with low bone mass. This study aims to see if it reduces bone loss more effectively than current treatments.
Health conditions and diseases that the clinical trial is designed to study and treat.
Osteoporosis is a condition characterized by weak and brittle bones, increasing the risk of fractures. It often develops silently over many years, making bones more susceptible to breaks.
Osteopenia is a condition where bone density is lower than normal, but not low enough to be classified as osteoporosis. It indicates an increased risk of developing osteoporosis in the future.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.